Hyaluronan nanocapsules as a new vehicle for intracellular drug delivery
Author
dc.contributor.author
Oyarzún Ampuero, Felipe
es_CL
Author
dc.contributor.author
Rivera Rodríguez, Gustavo R.
es_CL
Author
dc.contributor.author
Alonso, Maria J.
es_CL
Author
dc.contributor.author
Torres, Dolores
Admission date
dc.date.accessioned
2014-02-06T19:24:47Z
Available date
dc.date.available
2014-02-06T19:24:47Z
Publication date
dc.date.issued
2013
Cita de ítem
dc.identifier.citation
European Journal of Pharmaceutical Sciences 49 (2013) 483–490
en_US
Identifier
dc.identifier.issn
doi 10.1016/j.ejps.2013.05.008
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/121823
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Here we report the development of new drug nanocarriers – named hyaluronan nanocapsules – for the
intracellular delivery of hydrophobic anticancer drugs. These nanocapsules are composed of a lipid core
and a shell of hyaluronic acid (HA). Nanocapsules were produced by a modified solvent displacement
technique, which allows the formation of the polymer shell around the oily core using a cationic surfactant
as an interphase bridge. The resulting nanocapsules have a size of 200 nm, a negative zeta potential
and a spherical shape. The model drug docetaxel could be efficiently encapsulated within their core. The
in vitro cell culture studies (NCI-H460 cancer cell line) showed that the cytotoxicity of docetaxel could be
significantly enhanced due to its encapsulation within the nanocapsules. Interestingly, the nanocapsules
were stable during storage and they could also be transformed into a powder by freeze-drying. These
novel nanostructures hold promise as intracellular drug delivery systems.